EMERGENT BIOSOLUTIONS CANADA INC

Emergent Biosolutions Canada Inc. specializes in the manufacturing of advanced pharmaceutical countermeasures, with a focus on biosafety-critical biologics including antitoxins and immune globulin products. Their technical expertise lies in the end-to-end production of specialized biopharmaceuticals under strict regulatory controls, encompassing purification, formulation, sterile filling, and quality assurance processes aligned with cGMP standards. The company demonstrates deep capability in the development and scalable manufacturing of antivenoms and passive immunotherapeutics, particularly for high-consequence pathogens such as botulinum neurotoxins. Their operational rigor ensures product stability, potency, and rapid deployment readiness, making them a trusted partner in national biodefense and public health emergency response. The contractor maintains a consistent relationship with the Department of Health and Human Services, delivering critical medical countermeasures under emergency preparedness and biodefense programs. Their work supports HHS’s mission to safeguard the U.S. population against biological threats through the production of life-saving therapeutics that require stringent cold-chain logistics, biosafety containment, and regulatory compliance under FDA and CDC frameworks. Emergent Biosolutions Canada Inc. operates primarily within NAICS 325412 — Pharmaceutical Preparation Manufacturing — focusing on the development of injectable biologics and immune-based therapeutics. This vertical specialization positions them at the intersection of public health security and advanced biomanufacturing, serving niche markets requiring high-containment facilities and specialized regulatory pathways for non-routine biologics. As a Canadian entity based in Winnipeg, Manitoba, the company functions under a corporate structure designated as 8H, indicating its status as a small business with no federal certifications on record. While geographically outside the U.S., its contractual engagement with U.S. federal agencies reflects its integration into the North American biosecurity supply chain, leveraging cross-border regulatory alignment and specialized manufacturing capacity for government-critical products.